Galectin-3 and post-myocardial infarction cardiac remodeling

European Journal of Pharmacology

Volumn 763, Issue , 2015, Pages 115-121

  Meijers, Wouter C ^a   Van Der Velde, A Rogier ^a   Pascual Figal, Domingo A ^b   De Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Biomarker; Fibrosis; Galectin 3; Heart failure; Myocardial infarction; Remodeling

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CELL PROTEIN; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; GALECTIN 3 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MINERALOCORTICOID ANTAGONIST; N ACETYLLACTOSAMINE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ARTICLE; ATRIAL FIBRILLATION; CARDIOMYOPATHY; CARDIOVASCULAR RISK; DISEASE COURSE; EXPERIMENTAL STUDY; GALECTIN 3 BLOOD LEVEL; GENE EXPRESSION REGULATION; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE REPAIR; UPREGULATION; ANIMAL; DRUG EFFECTS; FIBROSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; MYOCARDIAL INFARCTION; PATHOLOGY;

ANIMALS; FIBROSIS; GALECTIN 3; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; VENTRICULAR REMODELING;

EID: 84941599684     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.06.025     Document Type: Article

References (67)

1. J. Abdulla, S. Barlera, R. Latini, L. Kjoller-Hansen, P. Sogaard, E. Christensen, L. Kober, and C. Torp-Pedersen A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction Eur. J. Heart Fail. 9 2 2007 129 135
2. I.S. Anand, T.S. Rector, M. Kuskowski, A. Adourian, P. Muntendam, and J.N. Cohn Baseline and serial measurements of galectin-3 in patients with heart failure: Relationship to prognosis and effect of treatment with valsartan in the val-HeFT Eur. J. Heart Fail. 15 5 2013 511 518
3. M.J. Andersen, M. Ersboll, J. Bro-Jeppesen, J.E. Moller, C. Hassager, L. Kober, B.A. Borlaug, J.P. Goetze, and F. Gustafsson Relationships between biomarkers and left ventricular filling pressures at rest and during exercise in patients after myocardial infarction J. Cardiac Fail. 20 12 2014 959 967
4. B.C. Berk, K. Fujiwara, and S. Lehoux ECM remodeling in hypertensive heart disease J. Clin. Investig. 117 3 2007 568 575
5. L. Calvier, E. Martinez-Martinez, M. Miana, V. Cachofeiro, E. Rousseau, J.R. Sadaba, F. Zannad, P. Rossignol, and N. Lopez-Andres The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries JACC. Heart Fail. 3 1 2015 59 67
6. L. Calvier, M. Miana, P. Reboul, V. Cachofeiro, E. Martinez-Martinez, R.A. de Boer, F. Poirier, P. Lacolley, F. Zannad, P. Rossignol, and N. Lopez-Andres Galectin-3 mediates aldosterone-induced vascular fibrosis Arterioscler. Thromb. Vasc. Biol. 33 1 2013 67 75
7. P. Chareonthaitawee, T.F. Christian, K. Hirose, R.J. Gibbons, and J.A. Rumberger Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction J. Am. Coll. Cardiol. 25 3 1995 567 573
8. J.P. Cleutjens, J.C. Kandala, E. Guarda, R.V. Guntaka, and K.T. Weber Regulation of collagen degradation in the rat myocardium after infarction J. Mol. Cell. Cardiol. 27 6 1995 1281 1292
9. W. Cui, H. Maimaitiyiming, X. Qi, H. Norman, and S. Wang Thrombospondin 1 mediates renal dysfunction in a mouse model of high-fat diet-induced obesity Am. J. Physiol. Renal Physiol. 305 6 2013 F871 80
10. R.A. de Boer, A.R. van der Velde, C. Mueller, D.J. van Veldhuisen, S.D. Anker, W.F. Peacock, K.F. Adams, and Al Maisel Galectin-3: a modifiable risk factor in heart failure Cardiovasc. Drugs Ther. 28 3 2014 237 246
11. R.A. de Boer, D.J. van Veldhuisen, R.T. Gansevoort, A.C. Muller Kobold, W.H. van Gilst, H.L. Hillege, S.J. Bakker, and P. van der Harst The fibrosis marker galectin-3 and outcome in the general population J. Int. Med. 272 1 2012 55 64
12. R.A. de Boer, A.A. Voors, P. Muntendam, W.H. van Gilst, and D.J. van Veldhuisen Galectin-3: a novel mediator of heart failure development and progression Eur. J. Heart Fail. 11 9 2009 811 817
13. A. Desmouliere, A. Geinoz, F. Gabbiani, and G. Gabbiani Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts J. Cell Biol. 122 1 1993 103 111
14. C. Drechsler, G. Delgado, C. Wanner, K. Blouin, S. Pilz, A. Tomaschitz, M.E. Kleber, A. Dressel, C. Willmes, V. Krane, B.K. Kramer, W. Marz, E. Ritz, W.H. van Gilst, P. van der Harst, and R.A. de Boer Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies J. Am. Soc. Nephrol. 2015 pii: ASN.2014010093. [Epub ahead of print]
15. J. Dumic, S. Dabelic, and M. Flogel Galectin-3: An open-ended story Biochim. Et Biophys. Acta 1760 4 2006 616 635
16. L.W. Eaton, J.L. Weiss, B.H. Bulkley, J.B. Garrison, and M.L. Weisfeldt Regional cardiac dilatation after acute myocardial infarction: Recognition by two-dimensional echocardiography N. Engl. J. Med. 300 2 1979 57 62
17. S.L. Farnworth, N.C. Henderson, A.C. Mackinnon, K.M. Atkinson, T. Wilkinson, K. Dhaliwal, K. Hayashi, A.J. Simpson, A.G. Rossi, C. Haslett, and T. Sethi Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function Am. J. Pathol. 172 2 2008 395 405
18. M.D. Filipe, W.C. Meijers, A. Rogier van der Velde, and R.A. de Boer Galectin-3 and heart failure: prognosis, prediction and clinical utility Clin. Chim. Acta; Int. J. Clin. Chem. 30 443 2015 48 56
19. A.R. Frenay, L. Yu, A.R. van der Velde, I. Vreeswijk-Baudoin, N. Lopez-Andres, H. van Goor, H.H. Sillje, W.P. Ruifrok, and R.A. de Boer Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy Am. J. Physiol. Renal Physiol. 308 5 2015 F500 9
20. G.E. Gonzalez, P. Cassaglia, S. Noli Truant, M.M. Fernandez, L. Wilensky, V. Volberg, E.L. Malchiodi, C. Morales, and R.J. Gelpi Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice Int. J. Cardiol. 176 3 2014 1423 1425
21. S. Hashmi, and S. Al-Salam Galectin-3 is expressed in the myocardium very early post-myocardial infarction Cardiovasc. Pathol. Off. J. Soc. Cardiovas. Pathol. 24 14 2014 pii S1054-8807 00160-4
22. N.C. Henderson, A.C. Mackinnon, S.L. Farnworth, T. Kipari, C. Haslett, J.P. Iredale, F.T. Liu, J. Hughes, and T. Sethi Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am. J. Pathol. 172 2 2008 288 298
23. N.C. Henderson, A.C. Mackinnon, S.L. Farnworth, F. Poirier, F.P. Russo, J.P. Iredale, C. Haslett, K.J. Simpson, and T. Sethi Galectin-3 regulates myofibroblast activation and hepatic fibrosis Proc. Natl. Acad. Sci. USA 103 13 2006 5060 5065
24. J.E. Ho, C. Liu, A. Lyass, P. Courchesne, M.J. Pencina, R.S. Vasan, M.G. Larson, and D. Levy Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J. Am. Coll. Cardiol. 60 14 2012 1249 1256
25. C. Iacobini, G. Oddi, S. Menini, L. Amadio, C. Ricci, C. Di Pippo, M. Sorcini, F. Pricci, F. Pugliese, and G. Pugliese Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice Am. J. Physiol. Renal Physiol. 289 3 2005 F611 21
26. S.T. Kelley, R. Malekan, J.H. Gorman 3rd, B.M. Jackson, R.C. Gorman, Y. Suzuki, T. Plappert, D.K. Bogen, M.G. Sutton, and L.H. Edmunds Jr. Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction Circulation 99 1 1999 135 142
27. M. Kolatsi-Joannou, K.L. Price, P.J. Winyard, and D.A. Long Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury PloS One 6 4 2011 e18683
28. N. Koleganova, G. Piecha, E. Ritz, R. Bekeredjian, P. Schirmacher, C.P. Schmitt, and M.L. Gross Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic Lab. Investig. J. Tech. Methods Pathol. 89 5 2009 520 530
29. C.M. Kramer, W.J. Rogers, C.S. Park, P.S. Seibel, A. Shaffer, T.M. Theobald, N. Reichek, T. Onodera, and A.M. Gerdes Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling J. Mol. Cell. Cardiol. 30 9 1998 1773 1778
30. M. Kruk, V. Menon, J. Kadziela, Z. Sadowski, W. Ruzyllo, J. Janas, M. Roik, G. Opolski, K. Zmudka, P. Czunko, M. Kurowski, B. Busz-Papiez, E. Zinka, W. Jablonski, K. Jaworska, A. Raczynska, G. Skonieczny, S. Forman, D. Li, and J. Hochman Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the occluded artery trial (OAT) biomarker ancillary study BMC Cardiovas. Disord. 13 2013 91
31. A. Lax, J. Sanchez-Mas, M.C. Asensio-Lopez, M.J. Fernandez-Del Palacio, L. Caballero, I.P. Garrido, F.J. Pastor-Perez, J.L. Januzzi, and D.A. Pascual-Figal Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction JACC. Heart Fail. 3 1 2014 50 58
32. C.P. Lexis, I.C. van der Horst, E. Lipsic, W.G. Wieringa, R.A. de Boer, A.F. van den Heuvel, H.W. van der Werf, R.A. Schurer, G. Pundziute, E.S. Tan, W. Nieuwland, H.M. Willemsen, B. Dorhout, B.H. Molmans, A.N. van der Horst-Schrivers, B.H. Wolffenbuttel, G.J. ter Horst, A.C. van Rossum, J.G. Tijssen, H.L. Hillege, B.J. de Smet, P. van der Harst, D.J. van Veldhuisen, and G.I.P.S.-I.I.I. Investigators Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial J. Am. Med. Assoc. 311 15 2014 1526 1535
33. Y.H. Liu, M. D'Ambrosio, T.D. Liao, H. Peng, N.E. Rhaleb, U. Sharma, S. Andre, H.J. Gabius, and O.A. Carretero N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin Am. J. Physiol. Heart Circ. Physiol. 296 2 2009 H404 12
34. D.J. Lok, S.I. Lok, P.W. Bruggink-Andre de la Porte, E. Badings, E. Lipsic, J. van Wijngaarden, R.A. de Boer, D.J. van Veldhuisen, and P. van der Meer Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure Clin. Res. Cardiol. 102 2013 103 110
35. B. López, A. González, R. Querejeta, E. Zubillaga, M. Larman, and J. Díez Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin Eur J Heart Fail. 17 4 2015 385 392
36. A.C. Mackinnon, M.A. Gibbons, S.L. Farnworth, H. Leffler, U.J. Nilsson, T. Delaine, A.J. Simpson, S.J. Forbes, N. Hirani, J. Gauldie, and T. Sethi Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3 Am. J. Respir. Crit. Care Med. 185 5 2012 537 546
37. A.C. Mackinnon, S.L. Farnworth, P.S. Hodkinson, N.C. Henderson, K.M. Atkinson, H. Leffler, U.J. Nilsson, C. Haslett, S.J. Forbes, and T. Sethi Regulation of aternative macrophage activation by galectin-3 J. Immuno. 180 4 2008 2650 2658
38. A. Maisel, Y. Xue, D.J. van Veldhuisen, A.A. Voors, T. Jaarsma, P.S. Pang, J. Butler, B. Pitt, P. Clopton, and R.A. de Boer Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study) Am. J. Cardiol. 114 5 2014 737 742
39. A. Mayr, G. Klug, J. Mair, K. Streil, B. Harrasser, H.J. Feistritzer, W. Jaschke, M. Schocke, O. Pachinger, and B. Metzler Galectin-3: relation to infarct scar and left ventricular function after myocardial infarction Int. J. Cardiol. 163 3 2013 335 337
40. R.J. McCormick, T.I. Musch, B.C. Bergman, and D.P. Thomas Regional differences in LV collagen accumulation and mature cross-linking after myocardial infarction in rats Am. J. Physiol. 266 1Pt 2 1994 H354 9
41. R.G. McKay, M.A. Pfeffer, R.C. Pasternak, J.E. Markis, P.C. Come, S. Nakao, J.D. Alderman, J.J. Ferguson, R.D. Safian, and W. Grossman Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion Circulation 74 4 1986 693 702
42. W.C. Meijers, J.L. Januzzi, C. deFilippi, A.S. Adourian, S.J. Shah, D.J. van Veldhuisen, and R.A. de Boer Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials Am. Heart J. 167 6 2014 853 860
43. W.C. Meijers, A.R. van der Velde, W.P. Ruifrok, N.F. Schroten, M.M. Dokter, K. Damman, S. Assa, C.F. Franssen, R.T. Gansevoort, W.H. van Gilst, H.H. Sillje, and R.A. de Boer Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis J. Am. Heart Assoc. 3 5 2014 e000962
44. S. Mendis, P. Puska, and B. Norrving Global Atlas on Cardiovascular Disease Prevention and Control 2011 World Health Organization Geneva
45. S. Menini, C. Iacobini, C. Ricci, C. Blasetti Fantauzzi, L. Salvi, C.M. Pesce, M. Relucenti, G. Familiari, M. Taurino, and G. Pugliese The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis Cardiovas. Res. 100 3 2013 472 480
46. S.R. Motiwala, J. Szymonifka, A. Belcher, R.B. Weiner, A.L. Baggish, P. Sluss, H.K. Gaggin, A. Bhardwaj, and J.L. Januzzi Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study Eur. J. Heart Fail. 15 10 2013 1157 1163
47. C.M. O'Seaghdha, S.J. Hwang, J.E. Ho, R.S. Vasan, D. Levy, and C.S. Fox Elevated galectin-3 precedes the development of CKD J. Am. Soc. Nephrol. 24 9 2013 1470 1477
48. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, and M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 14 2003 1309 1321
49. J. Raimond, D.B. Zimonjic, C. Mignon, M. Mattei, N.C. Popescu, M. Monsigny, and A. Legrand Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22 Mamm. Genome: Off. J. Int. Mamm. Genome Soc. 8 9 1997 706 707
50. M.B. Ratcliffe Non-ischemic infarct extension: a new type of infarct enlargement and a potential therapeutic target J. Am. Coll. Cardiol. 40 6 2002 1168 1171
51. V. Robert, C. Heymes, J.S. Silvestre, A. Sabri, B. Swynghedauw, and C. Delcayre Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis Hypertension 33 4 1999 981 986
52. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, W.B. Borden, D.M. Bravata, S. Dai, E.S. Ford, C.S. Fox, H.J. Fullerton, C. Gillespie, S.M. Hailpern, J.A. Heit, V.J. Howard, B.M. Kissela, S.J. Kittner, D.T. Lackland, J.H. Lichtman, L.D. Lisabeth, D.M. Makuc, G.M. Marcus, A. Marelli, D.B. Matchar, C.S. Moy, D. Mozaffarian, M.E. Mussolino, G. Nichol, N.P. Paynter, E.Z. Soliman, P.D. Sorlie, N. Sotoodehnia, T.N. Turan, S.S. Virani, N.D. Wong, D. Woo, M.B. Turner, American Heart Association Statistics Committee, and Stroke Statistics Subcommittee Executive summary: Heart disease and stroke statistics - 2012 update: a report from the american heart association Circulation 125 1 2012 188 197
53. J. Sanchez-Mas, A. Lax, M.C. Asensio-Lopez, M.J. Fernandez-Del Palacio, L. Caballero, I.P. Garrido, F. Pastor, J.L. Januzzi, and D.A. Pascual-Figal Galectin-3 expression in cardiac remodeling after myocardial infarction Int. J. Cardiol. 172 1 2014 e98 e101
54. U.C. Sharma, S. Pokharel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, B. Schroen, S. Andre, H.J. Crijns, H.J. Gabius, J. Maessen, and Y.M. Pinto Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 19 2004 3121 3128
55. J.S. Silvestre, C. Heymes, A. Oubenaissa, V. Robert, B. Aupetit-Faisant, A. Carayon, B. Swynghedauw, and C. Delcayre Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis Circulation 99 20 1999 2694 2701
56. Y. Sun, J.P. Cleutjens, A.A. Diaz-Arias, and K.T. Weber Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat Cardiovas. Res. 28 9 1994 1423 1432
57. M.G. Sutton, and N. Sharpe Left ventricular remodeling after myocardial infarction: pathophysiology and therapy Circulation 101 25 2000 2981 2988
58. I. Szadkowska, R.N. Wlazel, M. Migala, K. Szadkowski, M. Zielinska, M. Paradowski, and L. Pawlicki The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty Cardiol. J. 20 6 2013 577 582
59. T.H. Tsai, P.H. Sung, L.T. Chang, C.K. Sun, K.H. Yeh, S.Y. Chung, S. Chua, Y.L. Chen, C.J. Wu, H.W. Chang, S.F. Ko, and H.K. Yip Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention J. Atheroscler. Thromb. 19 12 2012 1073 1082
60. A.R. van der Velde, L. Gullestad, T. Ueland, P. Aukrust, Y. Guo, A. Adourian, P. Muntendam, D.J. van Veldhuisen, and R.A. de Boer Prognostic value of changes in galectin-3 levels over time in patients with heart failure: Data from CORONA and COACH Circ. Heart Fail. 6 2 2013 219 226
61. A.R. van der Velde, C.P. Lexis, W.C. Meijers, I.C. van der Horst, E. Lipsic, M.M. Dokter, P. van der Harst, and R.A. de Boer Galectin-3 predicts left ventricular ejection fraction after myocardial infarction [Abstract] Circulation 130 A18665 2014
62. W.H. van Gilst, J.H. Kingma, K.H. Peels, J.H. Dambrink, and M. St John Sutton Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? results of one-year serial echocardiographic follow-up from the captopril and thrombolysis study (CATS) J. Am. Coll. Cardiol. 28 1 1996 114 121
63. K.T. Weber Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation Circulation 96 11 1997 4065 4082
64. R.A. Weir, C.J. Petrie, C.A. Murphy, S. Clements, T. Steedman, A.M. Miller, I.B. McInnes, I.B. Squire, L.L. Ng, H.J. Dargie, and J.J. McMurray Galectin-3 and cardiac function in survivors of acute myocardial infarction Circ. Heart Fail. 6 3 2013 492 498
65. H.D. White, R.M. Norris, M.A. Brown, P.W. Brandt, R.M. Whitlock, and C.J. Wild Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction Circulation 76 1 1987 44 51
66. L. Yu, W.P. Ruifrok, M. Meissner, E.M. Bos, H. van Goor, B. Sanjabi, P. van der Harst, B. Pitt, I.J. Goldstein, J.A. Koerts, D.J. van Veldhuisen, R.A. Bank, W.H. van Gilst, H.H. Sillje, and R.A. de Boer Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis Circ. Heart Fail. 6 1 2013 107 117
67. M. Zeisberg, and R. Kalluri Cellular mechanisms of tissue fibrosis. 1. common and organ-specific mechanisms associated with tissue fibrosis Am. J. Physiol.Cell Physiol. 304 3 2013 C216 25